Brukinsa (zanubrutinib)

Numéro de dossier de l’APP: 21965
État des négociations:
Negotiations were not pursued
Indication(s):
For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Promoteur/fabricant:
BeiGene, Ltd.
Numéro de projet de l’ACMTS:
PC0267
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation: